Abstract
Access to safe Water, Sanitation and Hygiene (WASH) services have been recognized as a highly precautionary measure essential to protecting human health during this COVID-19 outbreak. However, it is currently unknown whether poor or non-availability of these services are also closely related to COVID-19 fatalities. We analysed the latest data on COVID-19 fatality rates in Sub Saharan Africa with indicators of safe water and sanitation governance to test this hypothesis. We found a strong correlation between a higher case fatality rate and poorer access to safe drinking water as well as safe sanitation. The Pearson correlation is stronger for access to safe sanitation (−0.30) compared to access to safe drinking water (−0.20). The Chad, Niger and Sierra Leone were amongst the countries with the highest fatality rates (>6.0) and also had particularly poor access to safe drinking water (<34%) and safe sanitation (<22%). The hypothesis of an association between COVID-19 fatalities and poor access to water and sanitation was confirmed by this study. However, our analysis does not establish causality. Given the increase spread of COVID-19 and related deaths, this analysis serves as an important reminder that safe water and sanitation services are key for public health interventions and highlights the need to prioritise this sector in all economies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not a clinical study
Funding Statement
This study received no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used are included in the manuscript
